Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24065093 | 1.00 | TSHR (0.41) | TSHRMEN1HTTKMT2AATM | |
| SCHEMBL6840726 | 1.00 | TSHR (0.41) | TSHRMEN1HTTKMT2AATM | |
| SCHEMBL6711723 | 1.00 | TSHR (0.41) | TSHRMEN1HTTKMT2AATM | |
| SCHEMBL5834230 | 1.00 | TSHR (0.41) | TSHRMEN1HTTKMT2AATM | |
| SCHEMBL6176681 | 0.88 | CES1 (0.40) | TSHRATMSMN1; SMN2NPSR1PTGDR2 | |
| SCHEMBL631003 | 0.88 | CES1 (0.40) | TSHRATMSMN1; SMN2NPSR1PTGDR2 | |
| SCHEMBL6173745 | 0.88 | CES1 (0.40) | TSHRATMSMN1; SMN2NPSR1PTGDR2 | |
| SCHEMBL5547851 | 0.87 | PTGDR2 (0.39) | TSHRMEN1KMT2AATMSMN1; SMN2 | |
| SCHEMBL1768237 | 0.87 | PTGDR2 (0.39) | TSHRMEN1KMT2AATMSMN1; SMN2 | |
| SCHEMBL4186204 | 0.87 | PTGDR2 (0.39) | TSHRMEN1KMT2AATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | disclosed |
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-12-30 | — | — | US | disclosed |
| US-12496351-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-12478695-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-11-25 | — | — | US | disclosed |
| US-12472265-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| US-12433950-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-10-07 | — | — | US | disclosed |
| US-12364767-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-07-22 | — | — | US | disclosed |
| US-12303571-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-05-20 | — | — | US | disclosed |
| US-12285491-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-04-29 | — | — | US | disclosed |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-02-11 | — | — | US | disclosed |
| US-7001916-B1 | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals | SCHERING, AG (DE) | 2006-02-21 | — | — | US | disclosed |
| US-20050037977-A1 | Compounds for treating tumors | WYETH HOLDINGS CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
| US-20040019086-A1 | Aminediols for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN | 2004-01-29 | — | — | US | disclosed |
| US-20030144523-A1 | EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-07-31 | — | — | US | disclosed |
| WO-2003006453-A1 | AMINEDIOLS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| EP-1161430-A2 | EPOTHILON DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE THEREOF AS PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000047584-A2 | EPOTHILON DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE THEREOF AS PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-08-17 | — | — | WO | disclosed |
| EP-1005465-A2 | NEW EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-06-07 | — | — | EP | disclosed |
| WO-2000000485-A1 | EPOTHILON DERIVATIVES, THEIR PREPARATION PROCESS, INTERMEDIATE PRODUCTS AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-01-06 | — | — | WO | disclosed |
| WO-1999007692-A2 | NEW EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD4, CD2, B2M | TSHR 1195/4885MEN1 780/4885HTT 3843/4885 |
| US-20050037977-A1 | Compounds for treating tumors | RB1, MRPL9, BCOR | TSHR 814/4885MEN1 323/4885HTT 4052/4885 |
| US-20030144523-A1 | EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | TUBB1, TUBA1C, TUBB4A | TSHR 668/4885MEN1 3225/4885HTT 2800/4885 |
| US-20040019086-A1 | Aminediols for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | TSHR 4072/4885MEN1 680/4885HTT 368/4885 |
| US-12433950-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | TSHR 3166/4885MEN1 2291/4885HTT 3736/4885 |
| US-12496351-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | TSHR 3166/4885MEN1 2291/4885HTT 3736/4885 |
| US-12303571-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | TSHR 3303/4885MEN1 196/4885HTT 4672/4885 |
| US-12285491-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | TSHR 3166/4885MEN1 2291/4885HTT 3736/4885 |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | TSHR 3303/4885MEN1 196/4885HTT 4672/4885 |
| US-12472265-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | TSHR 3166/4885MEN1 2291/4885HTT 3736/4885 |
| US-12478695-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | TSHR 3303/4885MEN1 196/4885HTT 4672/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | TSHR 588/4885MEN1 2393/4885HTT 3952/4885 |
| US-12364767-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | TSHR 3166/4885MEN1 2291/4885HTT 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.